Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Hartmann

Showing results (191-200 of 198) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 198 results.
Pharmacogenetics and Genomics|March 13, 2008
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipientsDennis A Hesselink, Ron H N van Schaik, Madelon van Agteren, et al.
Kidney International|November 29, 2013
Long-term risks for kidney donorsGeir Mjøen, Stein Hallan, Anders Hartmann, et al.
Kidney International|October 2, 2004
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trialBengt Fellström, Hallvard Holdaas, Alan G Jardine, et al.
Lancet (London, England)|June 20, 2003
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialHallvard Holdaas, Bengt Fellström, Alan G Jardine, et al.
Therapeutic Drug Monitoring|July 22, 2008
AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphismMadelon van Agteren, Victor W Armstrong, Ron H N van Schaik, et al.
Transplantation|October 24, 2008
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trialTeun van Gelder, Helio Tedesco Silva, Johan W de Fijter, et al.
Kidney Medicine|January 3, 2023
Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical TrialObbo W Bredewold, Joe Chan, My Svensson, et al.
Frontiers in Transplantation|June 29, 2026
An exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial functionEdwin O W Bredewold, Rudmer J Postma, Joe Chan, et al.
Pageof 20

Showing results (191-200 of 198) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 198 results.
Pharmacogenetics and Genomics|March 13, 2008
CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipientsDennis A Hesselink, Ron H N van Schaik, Madelon van Agteren, et al.
Kidney International|November 29, 2013
Long-term risks for kidney donorsGeir Mjøen, Stein Hallan, Anders Hartmann, et al.
Kidney International|October 2, 2004
Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trialBengt Fellström, Hallvard Holdaas, Alan G Jardine, et al.
Lancet (London, England)|June 20, 2003
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trialHallvard Holdaas, Bengt Fellström, Alan G Jardine, et al.
Therapeutic Drug Monitoring|July 22, 2008
AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphismMadelon van Agteren, Victor W Armstrong, Ron H N van Schaik, et al.
Transplantation|October 24, 2008
Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trialTeun van Gelder, Helio Tedesco Silva, Johan W de Fijter, et al.
Kidney Medicine|January 3, 2023
Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical TrialObbo W Bredewold, Joe Chan, My Svensson, et al.
Frontiers in Transplantation|June 29, 2026
An exploration of markers of microvascular dysfunction in kidney transplant recipients randomized to belatacept: no clinical impact of CNIs on endothelial functionEdwin O W Bredewold, Rudmer J Postma, Joe Chan, et al.
Pageof 20